Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
出版年份 2017 全文链接
标题
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
作者
关键词
Palbociclib, Ribociclib, Abemaciclib, Hematological toxicity, Breast cancer
出版物
Breast Cancer
Volume 25, Issue 1, Pages 17-27
出版商
Springer Nature
发表日期
2017-11-16
DOI
10.1007/s12282-017-0818-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- (2017) Shaimaa Lasheen et al. Expert Review of Anticancer Therapy
- Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches
- (2017) Jennifer J. Griggs et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
- (2015) W. Hu et al. CLINICAL CANCER RESEARCH
- A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
- (2015) Zahi Mitri et al. INVESTIGATIONAL NEW DRUGS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Announcing a New Journal Section: Community Outreach
- (2015) M. Evans et al. ONCOLOGIST
- Cell Cycle Inhibitors Make Progress
- (2014) Vicki Brower JNCI-Journal of the National Cancer Institute
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started